We are international
Donate
• IMF TV TEXT SIZE   
webcasts from medical meetings    back

Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone.
06.10.07
Jean Luc Harousseau, MD
CHU Hotel Dieu
Nantes, France


 related articles